Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.86 USD | +0.71% | +9.30% | -11.50% |
May. 08 | Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating | MT |
May. 07 | Transcript : Pacira BioSciences, Inc., Q1 2024 Earnings Call, May 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.50% | 1.38B | |
+32.36% | 698B | |
+26.51% | 568B | |
-4.40% | 358B | |
+19.46% | 328B | |
+3.50% | 283B | |
+16.34% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+8.62% | 165B |
- Stock Market
- Equities
- PCRX Stock
- News Pacira BioSciences, Inc.
- Pacira BioSciences Says US FDA Granted Knee Osteoarthritis Therapy Candidate RMAT Designation